• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Sangamo Therapeutics Inc.

    8/16/24 6:40:25 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SGMO alert in real time by email
    SC 13G/A 1 d853462dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    SANGAMO THERAPEUTICS, INC.

    (Name of Issuer)

    Common Stock, $0.01 par value

    (Title of Class of Securities)

    800677106

    (CUSIP Number)

    August 14, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 800677106

     

     1.   

     Names of Reporting Persons.

     

     Biogen Inc. 33-0112644

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.    

     Sole Voting Power

     

       6.   

     Shared Voting Power

     

     3,250,000

       7.   

     Sole Dispositive Power

     

       8.   

     Shared Dispositive Power

     

     3,250,000

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     3,250,000 shares

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)1

     

     1.6%

    12.  

     Type of Reporting Person (See Instructions)

     

     CO


    CUSIP No. 800677106

     

     1.   

     Names of Reporting Persons.

     

     Biogen MA Inc.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     MASSACHUSETTS

    Number of

    Shares Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.    

     Sole Voting Power

     

       6.   

     Shared Voting Power

     

     3,250,000

       7.   

     Sole Dispositive Power

     

       8.   

     Shared Dispositive Power

     

     3,250,000

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     3,250,000 shares

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)1

     

     1.6%

    12.  

     Type of Reporting Person (See Instructions)

     

     CO

     

    (1)

    The percent ownership is calculated based upon an aggregate of 208,220,670 shares of common stock outstanding as of August 2, 2024, as reported in the Sangamo Therapeutics, Inc. Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2024.


    AMENDMENT NO. 1 TO SCHEDULE 13G (FINAL AMENDMENT)

    Reference is hereby made to the statement on Schedule 13G relating to the Common Stock of the Issuer filed with the Securities and Exchange Commission by the Reporting Persons on April 17, 2020 (the “Schedule 13G”). Terms defined in the Schedule 13G are used herein as so defined.

    The following items of the Schedule 13G are hereby amended and restated as follows:

     

    Item 4.    Ownership.
      

    (a)   Amount beneficially owned:

      

    See Row 9 of cover page.

      

    (b)   Percent of class:

      

    See Row 11 of cover page.

      

    (c)   Number of shares as to which the person has:

      

    (i) Sole power to vote or to direct the vote:

      

    See Row 5 of cover page.

      

    (ii)  Shared power to vote or to direct the vote:

      

    See Row 6 of cover page.

      

    (iii)  Sole power to dispose or to direct the disposition of:

      

    See Row 7 of cover page.

      

    (iv) Shared power to dispose or to direct the disposition of:

      

    See Row 8 of cover page.

    Item 5.    Ownership of 5 Percent or Less of a Class.
       If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete, and correct.

     

    BIOGEN INC.
    By:   /s/ Michael Dambach
      Name: Michael Dambach
      Title: Treasurer
    BIOGEN MA INC.
    By:   /s/ Michael Dambach
      Michael Dambach
      Treasurer

    Date: August 16, 2024

    Get the next $SGMO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SGMO

    DatePrice TargetRatingAnalyst
    12/13/2024$7.00Hold → Buy
    Truist
    12/10/2024$10.00Buy
    H.C. Wainwright
    11/3/2023$6.00 → $2.00Outperform → Sector Perform
    RBC Capital Mkts
    4/28/2023$5.00 → $1.50Neutral → Underperform
    BofA Securities
    2/27/2023$16.00Neutral → Outperform
    Wedbush
    1/6/2023$8.00 → $5.00Buy → Neutral
    BofA Securities
    6/13/2022$5.00Neutral
    Wedbush
    More analyst ratings

    $SGMO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sangamo Therapeutics upgraded by Truist with a new price target

      Truist upgraded Sangamo Therapeutics from Hold to Buy and set a new price target of $7.00

      12/13/24 8:18:20 AM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright reiterated coverage on Sangamo Therapeutics with a new price target

      H.C. Wainwright reiterated coverage of Sangamo Therapeutics with a rating of Buy and set a new price target of $10.00

      12/10/24 11:58:57 AM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics downgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts downgraded Sangamo Therapeutics from Outperform to Sector Perform and set a new price target of $2.00 from $6.00 previously

      11/3/23 7:45:03 AM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care